Biểu đồ giá cổ phiếu NUVL
NUVL Dự đoán giá cổ phiếu
Nuvalent, Inc
$123.9
0.05%
$0.07
Khi đóng cửa: Jul 10, 16:00:00 GMT-4
$123.94
0.03%
$0.03
Phiên sau giờ: Jul 10, 20:00:00 GMT-4
Quay lại
Nuvalent, Inc (NUVL) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$123.83
Giá mở cửa
$123.87
Phạm vi ngày
$123.83 - $123.95
Phạm vi 52 tuần
$71.13 - $123.94
Khối lượng
2.0M
Khối lượng trung bình
1.5M
Tỷ suất cổ tức
--
EPS (TTM)
-6.05
Vốn hóa thị trường
$9.8B
NUVL là gì?
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
